Granules India Limited

Rs.3,183

US FDA remediation activities. ▪ Cashflow From Operations: Healthy cash flow from operations of Rs.3,183 Mn with a Net Debt to EBITDA ratio of 0.75x. ▪ Senn Chemicals AG (Peptide CDMO) acquisition: Succ

0.75x

m Operations: Healthy cash flow from operations of Rs.3,183 Mn with a Net Debt to EBITDA ratio of 0.75x. ▪ Senn Chemicals AG (Peptide CDMO) acquisition: Successfully completed the 100% acquisition on 1

100%

BITDA ratio of 0.75x. ▪ Senn Chemicals AG (Peptide CDMO) acquisition: Successfully completed the 100% acquisition on 10th April’25 ▪ GLS Phase II: Inaugurated the 7.5Bn formulation dosages facility

2%

nce Q4 FY25 Q4 FY24 Y-o-Y Gr% Remarks on Y-o-Y performance (In ₹ Mn) Revenue 11,974 11,758 2% YoY growth in FD has been offset by the continued decline in API/PFI due to persistent price eros

63.4%

due to persistent price erosion Gross Margin Gross Margin % EBITDA EBITDA % PAT PAT % 7,591 63.4% 2,524 21.1% 1,520 12.7% 7,061 60.1% 2,557 21.7% 1,296 11.0% 7% -1% 17% Achieved bette

21.1%

ent price erosion Gross Margin Gross Margin % EBITDA EBITDA % PAT PAT % 7,591 63.4% 2,524 21.1% 1,520 12.7% 7,061 60.1% 2,557 21.7% 1,296 11.0% 7% -1% 17% Achieved better margins by s

12.7%

ion Gross Margin Gross Margin % EBITDA EBITDA % PAT PAT % 7,591 63.4% 2,524 21.1% 1,520 12.7% 7,061 60.1% 2,557 21.7% 1,296 11.0% 7% -1% 17% Achieved better margins by selling higher

60.1%

gin Gross Margin % EBITDA EBITDA % PAT PAT % 7,591 63.4% 2,524 21.1% 1,520 12.7% 7,061 60.1% 2,557 21.7% 1,296 11.0% 7% -1% 17% Achieved better margins by selling higher margin finish

21.7%

gin % EBITDA EBITDA % PAT PAT % 7,591 63.4% 2,524 21.1% 1,520 12.7% 7,061 60.1% 2,557 21.7% 1,296 11.0% 7% -1% 17% Achieved better margins by selling higher margin finished dosage (FD)

11.0%

EBITDA % PAT PAT % 7,591 63.4% 2,524 21.1% 1,520 12.7% 7,061 60.1% 2,557 21.7% 1,296 11.0% 7% -1% 17% Achieved better margins by selling higher margin finished dosage (FD) Professional

7%

% PAT PAT % 7,591 63.4% 2,524 21.1% 1,520 12.7% 7,061 60.1% 2,557 21.7% 1,296 11.0% 7% -1% 17% Achieved better margins by selling higher margin finished dosage (FD) Professional exp

1%

AT PAT % 7,591 63.4% 2,524 21.1% 1,520 12.7% 7,061 60.1% 2,557 21.7% 1,296 11.0% 7% -1% 17% Achieved better margins by selling higher margin finished dosage (FD) Professional expenses

“Waste generated sent for Co-processing Earnings Presentation – FY25 and Q4 FY 25 31 CCC AAAAAA Social Impact Initiative : Pharma Pathshala at Swarna Bharat Trust Granules initiative to train a rural workforce through the Swarna Bharat Trust 1,450+ Students trained through Pharma Pathshala Earnings Presentation – FY25 and Q4 FY25 32 For investor relation – Granules IR desk Email: investorrelations@granulesindia.com www.granulesindia.com Ms.”

Prioritizing OTC business through GCH and GPAK

1

Corporate address

1

Prioritizing OTC business through GCH and GPAK

Growing OTC business through partnership with Brand owners and leading Retailers in the US. Business Growth to be driven by primarily new launches, both in Rx and OTC, supplemented by BD in new dosage forms 4,157 FY 15 FY 16 FY 17 FY 18 FY 19 FY 20 FY 21 FY 22 FY 23 FY 24 FY 25 Earnings Presentation – FY25 and Q4 FY25 25 Business Strategy : Expanding Reach Through Commercial Excellence Replicate commercial success of North America in other key markets Strengthening Teams | Building Commercial Excellence Processes ▪ Revamped and augmented Commercial leadership team ▪ Formulation Driven Growth in Europe through key partnerships and Dossier Sales/ BD Deals on existing and New Products ▪ Extension of the Commercial portfolio and new products ▪ Customer focus: New Initiatives focus on customer service excellence Earnings Presentation – FY25 and Q4 FY25 26 Business Strategy: Building R&D Capability and Product Pipeline R&D Expenditure (INR Mn) R&D Exp % to Sales ~405 # Scientists Across API

Corporate address

15th Floor, Granules Tower, Botanical Garden road, Kondapur, Hyderabad - 500084 CIN: L24110TG1991PLC012471 Voice: +91 40 69043500 www.granulesindia.com 532482 GRANULES GRAN:IN GRAN:NS 33